Cover Image

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study

Background: Ceftolozane-tazobactam is an emerging ‎treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas ‎aeruginosa. However, limited ‎data support its use in bacteremia treatment. This study aimed to assess the effectiveness of the treatment of MDR P. aeruginosa bacteremi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hakeam A. Hakeam (Author), Ghadi Askar (Author), Khalid Al Sulaiman (Author), Reem Mansour (Author), Maha M. Al Qahtani (Author), Dana Abbara (Author), Nada Aldhayyan (Author), Nariman Dyab (Author), Liyan Afaneh (Author), Muna Islami (Author), Zainab Al Duhailib (Author)
Format:	Book
Published:	Elsevier, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020)

Ceftolozane/tazobactam for the treatment of bacteremia: a systematic literature review (SLR)
by: Z. S. Khankhel, et al.
Published: (2022)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021)

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition
by: Jan Thomas De Pourcq, et al.
Published: (2024)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020)

Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019)

Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
by: Li-Ting Wang, et al.
Published: (2021)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020)

Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022)

Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
by: Silvia Garazzino, et al.
Published: (2020)

Activity of Ceftolozane/tazobactam and Imipenem/relebactam against Clinical Enterobacteriaceae Isolates Collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical P. aeruginosa isolates collected in the Middle East - SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020)

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam
by: Jade L. L. Teng, et al.
Published: (2024)

Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice
by: Bryan Hausman, et al.
Published: (2024)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023)

Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals
by: Anis Karuniawati, et al.
Published: (2022)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting
by: Francesco Venuti, et al.
Published: (2023)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022)

Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
by: Laila M. Najia, et al.
Published: (2023)

Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Enterobacterales</i> from Five Latin American Countries
by: Juan Carlos García-Betancur, et al.
Published: (2022)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
by: Mohammed Al Nuhait, et al.
Published: (2018)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021)

Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem
by: Majed S. Al Yami
Published: (2017)

Piperacillin/Tazobactam (ZOSYN)
by: Stephanie M. Culver, et al.
Published: (1996)